FDA approves Bioness movement device

March 03, 2017
Bioness Inc. received clearance from the U.S. Food and Drug Administration for its NESS L300 Plus System. The device combines the company's NESS L300 Foot Drop System with a thigh stimulation cuff, to provide knee flexion and extension in addition to ankle dorsiflexion during gait. The NESS L300 Plus is intended for persons with upper motor neuron injury or disease, such as multiple sclerosis. The device also may facilitate muscle re-education, prevent/retard muscle atrophy, maintain or increase range of motion and increase local blood flow.

People with upper motor neuron injuries or diseases often experience gait movement disorders such as foot drop, which is a result of partial leg paralysis. Gait movement disorders not only result in difficulty walking, but may also lead to fatigue, falls or abnormal walking patterns.

The NESS L300 Plus is designed to additionally stimulate the muscles of the thigh. The addition of the thigh stimulation cuff, synchronized with a wireless heel sensor to detect when the foot is on or off the ground, controls the knee, making it easier to walk. Historically, patients have relied on rigid plastic braces which restrict thigh and ankle movements and can lead to additional problems, including increased falls.

The company anticipates the device will become commercially available to neurorehabilitation hospitals and centers around the country and to consumers for home use within the coming weeks.

MS Focus Lending Library


Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Dress4MS with Sharon Osbourne


Dress up to show your support for those affected with MS
Learn more